Superior therapy response predictions for patients with glioblastoma (GBM) using Cellworks Singula: MyCare-009-03

Singula is a superior predictor of PFS and OS in GBM patients compared to PPT. Singula can identify non-responders to PPT and provide alternative therapy selections.